{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T19:32:05Z","timestamp":1725823925271},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1998,6,1]],"date-time":"1998-06-01T00:00:00Z","timestamp":896659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. J. Clin. Microbiol. Infect. Dis."],"published-print":{"date-parts":[[1998,6]]},"DOI":"10.1007\/bf01691573","type":"journal-article","created":{"date-parts":[[2005,5,15]],"date-time":"2005-05-15T02:50:19Z","timestamp":1116125419000},"page":"405-412","source":"Crossref","is-referenced-by-count":9,"title":["Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens"],"prefix":"10.1007","volume":"17","author":[{"given":"J. -C.","family":"Pech\u00e8re","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. D.","family":"Gootz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01691573_CR1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00001432-199612000-00003","volume":"9","author":"F Baquero","year":"1996","unstructured":"Baquero F: Epidemiology and management of penicillin-resistant pneumococci. Current Opinion in Infectious Diseases (1996) 9:372\u2013379","journal-title":"Current Opinion in Infectious Diseases"},{"issue":"Supplement B","key":"BF01691573_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/39.suppl_2.1","volume":"39","author":"KE Brighty","year":"1997","unstructured":"Brighty KE, Gootz TD: The chemistry and biological profile of trovafloxacin. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B:1\u201314","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691573_CR3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/(SICI)1098-1128(199609)16:5<433::AID-MED3>3.0.CO;2-W","volume":"16","author":"TD Gootz","year":"1996","unstructured":"Gootz TD, Brighty KE: Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects. Medicinal Research Reviews (1996) 16:433\u2013486","journal-title":"Medicinal Research Reviews"},{"issue":"Supplement 2","key":"BF01691573_CR4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF01793570","volume":"22","author":"B Wiedemann","year":"1994","unstructured":"Wiedemann B, Heisig P: Mechanisms of quinolone resistance. Infection (1994) 22, Supplement 2:73\u201379","journal-title":"Infection"},{"key":"BF01691573_CR5","first-page":"53","volume-title":"Quinolone antimicrobial agents","author":"DC Hooper","year":"1993","unstructured":"Hooper DC, Wolfson JS: Mechanisms of quinolone action and bacterial killing. In: Hooper DC, Wolfson JS (eds): Quinolone antimicrobial agents. American Society for Microbiology, Washington, DC (1993), pp 53\u201375"},{"key":"BF01691573_CR6","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1128\/AAC.38.11.2623","volume":"38","author":"K Hoshino","year":"1994","unstructured":"Hoshino K, Kitamura A, Morrissey I, Sato K, Kato J, Ikeda H: Comparison of inhibition ofEscherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrobial Agents and Chemotherapy (1994) 38:2623\u20132627","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2958.1994.tb01297.x","volume":"14","author":"RJ Belland","year":"1994","unstructured":"Belland RJ, Morrisson SG, Ison C, Huang WM:Neisseria gonorrhoeae acquires mutations in analogous regions ofgyrA andparC in fluoroquinolone-resistant isolates. Molecular Microbiology (1994) 14:371\u2013380","journal-title":"Molecular Microbiology"},{"key":"BF01691573_CR8","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1128\/AAC.39.7.1554","volume":"39","author":"L Ferrero","year":"1995","unstructured":"Ferrero L, Cameron B, Crouzet J: Analysis ofgyrA andgrlA mutations in stepwise-selected ciprofloxacin-resistant mutants ofStaphylococcus aureus. Antimicrobial Agents and Chemotherapy (1995) 39:1554\u20131558","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR9","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1128\/AAC.40.12.2691","volume":"40","author":"TD Gootz","year":"1996","unstructured":"Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, Courvalin P, Polzer RJ: Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants ofStreptococcus pneumoniae selected in vitro. Antimicrobial Agents and Chemotherapy (1996) 40:2691\u20132697","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0732-8893(94)90037-X","volume":"19","author":"TD Gootz","year":"1994","unstructured":"Gootz TD, Brighty KE, Anderson MR, Schmeider BJ, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk PR: In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl)naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease (1994) 19:235\u2013243","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"BF01691573_CR11","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1128\/jb.175.5.1484-1492.1993","volume":"175","author":"SP Cohen","year":"1993","unstructured":"Cohen SP, Hachler H, Levy SB: Genetic and functional analysis of the multiple antibiotic resistance (mar) locus inEscherichia coli. Journal of Bacteriology (1993) 175:1484\u20131492","journal-title":"Journal of Bacteriology"},{"key":"BF01691573_CR12","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/infdis\/163.5.1080","volume":"163","author":"GW Kaatz","year":"1991","unstructured":"Kaatz GW, Seo SM, Ruble CA: Mechanisms of fluoroquinolone resistance inStaphylococcus aureus. Journal of Infectious Diseases (1991) 163:1080\u20131086","journal-title":"Journal of Infectious Diseases"},{"key":"BF01691573_CR13","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1128\/jb.173.18.5854-5860.1991","volume":"173","author":"M Trucksis","year":"1991","unstructured":"Trucksis M, Wolfson JS, Hooper DC: A novel locus conferring fluoroquinolone resistance inStaphylococcus aureus. Journal of Bacteriology (1991) 173:5854\u20135860","journal-title":"Journal of Bacteriology"},{"key":"BF01691573_CR14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/jac\/38.2.324","volume":"38","author":"AL Barry","year":"1996","unstructured":"Barry AL, Brown SD, Fuchs PC: In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219). Journal of Antimicrobial Chemotherapy (1996) 38:324\u2013327","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691573_CR15","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/AAC.41.11.2540","volume":"41","author":"T K\u00f6hler","year":"1997","unstructured":"K\u00f6hler T, Mich\u00e9a-Hamzehpoor M, Pl\u00e9siat P, Kahr AL, Pech\u00e8re J-C: Differential selection of multidrug efflux systems of quinolones inPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy (1997) 41:2540\u20132543","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR16","volume-title":"Approved standard M7A3","author":"National Committee for Clinical Laboratory Standards","year":"1990","unstructured":"National Committee for Clinical Laboratory Standards: Standard methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7A3. NCCLS, Villanova, PA (1990)"},{"key":"BF01691573_CR17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/BF01691157","volume":"15","author":"B Olsson-Liljequist","year":"1996","unstructured":"Olsson-Liljequist B, Hoffman BM, Hedlund J: Activity of trovafloxacin against blood isolates ofStreptococcus pneumoniae in Sweden. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:671\u2013675","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"Supplement B","key":"BF01691573_CR18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/39.suppl_2.57","volume":"39","author":"AM Sefton","year":"1997","unstructured":"Sefton AM, Maskell JP, Rafay AM, Whiley A, Williams JD: The in-vitro activity of trovafloxacin, a new fluoroquinolone against gram-positive bacteria. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 57\u201362","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Supplement B","key":"BF01691573_CR19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jac\/39.suppl_2.43","volume":"39","author":"D Felmingham","year":"1997","unstructured":"Felmingham D, Robbins MJ, Ingley K, Mathias I, Bhogal H, Leakey A, Ridgway GL, Gr\u00fcneberg RN: In-vitro activity of trovafloxacin (CP-99,219), a new fluoroquinolone, against recent clinical isolates. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 43\u201349","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Supplement B","key":"BF01691573_CR20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jac\/39.suppl_2.15","volume":"39","author":"KVI Rolston","year":"1997","unstructured":"Rolston KVI, Ho DH, LeBlanc B, Streeter H, Dvorak T: In-vitro activity of CP-99,219, a novel azabicyclo-naphthyridone, against clinical bacterial isolates from patients with cancer. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 15\u201322","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691573_CR21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/BF01691161","volume":"15","author":"P Urb\u00e1skov\u00e1","year":"1996","unstructured":"Urb\u00e1skov\u00e1 P, Trupl J, Hupkov\u00e1 H, Appelbaum PC, Jacobs MR: In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:686\u2013688","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"BF01691573_CR22","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/BF01691164","volume":"15","author":"F Crokaert","year":"1996","unstructured":"Crokaert F, Aoun M, Duchateau V, Grenier P, Vandermies A, Klastersky J: In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:696\u2013698","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"BF01691573_CR23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/39.3.405","volume":"39","author":"D Shonekan","year":"1997","unstructured":"Shonekan D, Handwerger S, Mildvan D: Comparative in-vitro activities of RP59500 (quinupristin\/dalfopristin), CL 329.998, CL331.002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against gram-positive bacteria. Journal of Antimicrobial Chemotherapy (1997) 39:405\u2013409","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691573_CR24","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/AAC.37.2.366","volume":"37","author":"GM Eliopoulos","year":"1993","unstructured":"Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC Jr: In vitro activity of CP-99,219, a new fluoroquinolone against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy (1993) 37:366\u2013370","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR25","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jac\/35.6.869","volume":"35","author":"J Child","year":"1995","unstructured":"Child J, Andrews J, Boswell F, Brenwald N, Wise R: The in-vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Journal of Antimicrobial Chemotherapy (1995) 35:869\u2013876","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691573_CR26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/BF01691160","volume":"15","author":"L Verbist","year":"1996","unstructured":"Verbist L, Verhaegen J: In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:683\u2013685","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"BF01691573_CR27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1128\/AAC.41.2.478","volume":"41","author":"KS Thomson","year":"1997","unstructured":"Thomson KS, Chartrand SA, Sanders CC, Block SL: Trovafloxacin, a new fluoroquinolone with potent activity againstStreptococcus pneumoniae. Antimicrobial Agents and Chemotherapy (1997) 41:478\u2013480","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/jac\/36.5.873","volume":"36","author":"K Klugman","year":"1995","unstructured":"Klugman K, Wasas A: In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and-resistantStreptococcus pneumoniae. Journal of Antimicrobial Chemotherapy (1995) 36:873\u2013874","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691573_CR29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/jac\/35.1.230","volume":"35","author":"GA Pankuch","year":"1995","unstructured":"Pankuch GA, Jacobs MR, Appelbaum PC: Activity of CP-99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosulfloxacin, sparfloxacin, and grepafloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy (1995) 35:230\u2013232","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691573_CR30","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1128\/AAC.38.11.2615","volume":"38","author":"HC Neu","year":"1994","unstructured":"Neu HC, Chin N: In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy (1994) 38:2615\u20132622","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1128\/AAC.37.2.349","volume":"37","author":"B Briggs-Gooding","year":"1993","unstructured":"Briggs-Gooding B, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy (1993) 37:349\u2013353","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Supplement B","key":"BF01691573_CR32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/39.suppl_2.29","volume":"39","author":"BA Cunha","year":"1997","unstructured":"Cunha BA, Qadri SMH, Ueno Y, Walters EA, Domenico P: Antibacterial activity of trovafloxacin (CP-99,219) against nosocomial gram-positive and gram-negative isolates. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 29\u201334","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691573_CR33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0732-8893(96)00161-7","volume":"26","author":"PC Fuchs","year":"1996","unstructured":"Fuchs PC, Barry AL, Brown SD: Tentative interpretative criteria for testing the susceptibility ofStreptococcus pneumoniae to eight fluoroquinolones. Diagnostic Microbiology and Infectious Disease (1996) 26:23\u201327","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"BF01691573_CR34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/BF01691159","volume":"15","author":"PC Fuchs","year":"1996","unstructured":"Fuchs PC, Barry AL, Brown SD, Sewell DL: In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:678\u2013682","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"Supplement B","key":"BF01691573_CR35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/jac\/39.suppl_2.35","volume":"39","author":"LM Dembry","year":"1997","unstructured":"Dembry LM, Farrell PA, Orcutt DR, Gerrity LA, Andriole VT: In-vitro activity of trovafloxacin (CP-99,219 against sensitive and resistant aerobic bacteria using the standard microdilution broth method and E-test. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 35\u201342","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691573_CR36","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1128\/AAC.40.10.2428","volume":"40","author":"L Mulazimoglu","year":"1996","unstructured":"Mulazimoglu L, Drenning SD, Yu VL: In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin againstStaphylococcus aureus andStaphylococcus epidermidis. Antimicrobial Agents and Chemotherapy (1996) 40:2428\u20132430","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR37","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/jac\/37.5.1011","volume":"37","author":"TM Coque","year":"1996","unstructured":"Coque TM, Singh KV, Murray BE: Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci. Journal of Antimicrobial Chemotherapy (1996) 37:1011\u20131016","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Supplement 21","key":"BF01691573_CR38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2165\/00003495-199500492-00043","volume":"49","author":"RN Jones","year":"1995","unstructured":"Jones RN: In vitro antimicrobial activity of CP-99,219-99, a new 7-azabicyclonaphthyridone. Drugs (1995) 49, Supplement 21:205\u2013207","journal-title":"Drugs"},{"key":"BF01691573_CR39","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jac\/37.4.847","volume":"37","author":"MG Cormican","year":"1996","unstructured":"Cormican MG, Jones RN: In-vitro activity of trovafloxacin (CP-99,219) tested by two methods against 150 vancomycin-resistant enterococcal isolates. Journal of Antimicrobial Chemotherapy (1996) 37:847\u2013849","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691573_CR40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0732-8893(94)00113-B","volume":"21","author":"C Freeman","year":"1995","unstructured":"Freeman C, Robinson A, Cooper B, Mazens-Sullivan M, Quintiliani R, Nightingale C: In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagnostic Microbiology and Infectious Disease (1995) 21:47\u201350","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"BF01691573_CR41","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.41.7.1475","volume":"41","author":"MA Visalli","year":"1997","unstructured":"Visalli MA, Bajaksouzian S, Jacobs MR, Appelbaum PC: Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrobial Agents and Chemotherapy (1997) 41:1475\u20131478","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR42","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1128\/AAC.40.6.1412","volume":"40","author":"RJ Fass","year":"1996","unstructured":"Fass RJ, Barnishan J, Solomon MC, Ayers LW: In vitro activities of quinolones, \u03b2-lactams, tobramycin and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrobial Agents and Chemotherapy (1996) 40:1412\u20131418","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR43","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1128\/AAC.41.9.2033","volume":"41","author":"PM Roblin","year":"1997","unstructured":"Roblin PM, Kutlin A, Hammerschlag MR: In vitro activity of trovafloxacin againstChlamydia pneumoniae. Antimicrobial Agents and Chemotherapy (1997) 41:2033\u20132034","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR44","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/AAC.40.2.314","volume":"40","author":"PH Edelstein","year":"1996","unstructured":"Edelstein PH, Edelstein MAC, Ren J, Polzer R, Gladue RP: Activity of trovafloxacin (CP-99,219) againstLegionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs withL. pneumophila pneumonia. Antimicrobial Agents and Chemotherapy (1996) 40:314\u2013319","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR45","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1128\/AAC.40.4.1048","volume":"40","author":"GE Kenny","year":"1996","unstructured":"Kenny GE, Cartwright FD: Susceptibilities ofMycoplasma pneumoniae, Mycoplasma hominis andUreaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrobial Agents and Chemotherapy (1996) 40:1048\u20131049","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR46","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1128\/AAC.39.10.2210","volume":"39","author":"AE Girard","year":"1995","unstructured":"Girard AE, Girard D, Gootz TD, Faiella JA, Cimochowski CR: In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens,Streptococcus pneumoniae andBacteroides fragilis. Antimicrobial Agents and Chemotherapy (1995) 39:2210\u20132216","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BF01691573_CR47","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/39.6.797","volume":"39","author":"JM Andrews","year":"1997","unstructured":"Andrews JM, Honeybourne D, Brenwald NP, Bannerjee D, Iredale M, Cunningham D, Wise R: Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. Journal of Antimicrobial Chemotherapy (1997) 39:797\u2013802","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691573_CR48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/AAC.42.4.862","volume":"42","author":"J-P Bedos","year":"1998","unstructured":"Bedos J-P, Rieux V, Bauchet J, Muffat-Joly M, Carbon C, Azoulay-Dupuis: Efficacy of trovafloxacin against penicillinsusceptible and multiresistant strains in a mouse pneumonia model. Antimicrobial Agents and Chemotherapy (1998) 42:862\u2013867","journal-title":"Antimicrobial Agents and Chemotherapy"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01691573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01691573\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01691573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T16:00:35Z","timestamp":1557244835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01691573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["BF01691573"],"URL":"https:\/\/doi.org\/10.1007\/bf01691573","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,6]]}}}